Patents by Inventor Shuling Guo
Shuling Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10184125Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TMPRSS6.Type: GrantFiled: December 21, 2017Date of Patent: January 22, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventor: Shuling Guo
-
Publication number: 20180273946Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: October 11, 2017Publication date: September 27, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Publication number: 20180230465Abstract: Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, A1ATD associated liver disease, and pulmonary disease, such as, A1ATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting A1AT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, A1ATD associated liver disease and pulmonary disease, such as, A1ATD associated pulmonary disease.Type: ApplicationFiled: September 19, 2017Publication date: August 16, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
-
Publication number: 20180223289Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TMPRSS6.Type: ApplicationFiled: December 21, 2017Publication date: August 9, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventor: Shuling Guo
-
Publication number: 20180105817Abstract: Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as polycythemia, hemochromatosis or ?-thalassemia can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to TMPRSS6.Type: ApplicationFiled: April 4, 2016Publication date: April 19, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Shuling Guo, Mariam Aghajan, Eric E. Swayze
-
Patent number: 9885047Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TMPRSS6.Type: GrantFiled: November 3, 2016Date of Patent: February 6, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventor: Shuling Guo
-
Publication number: 20170335322Abstract: In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the target nucleic acid is a nucleic acid that encodes cartilage oligomeric matrix protein. In certain embodiments, the target nucleic acid is a nucleic acid expressed in the growth plate, tendon, or cartilage.Type: ApplicationFiled: November 12, 2015Publication date: November 23, 2017Applicants: Ionis Pharmaceuticals, Inc., Board of Regents of the University of Texas SystemInventors: Shuling Guo, Punit P. Seth, Jacqueline T. Hecht, Karen LaShea Posey
-
Patent number: 9816092Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: GrantFiled: June 23, 2016Date of Patent: November 14, 2017Assignee: Ionis Phamaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Patent number: 9796976Abstract: Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, A1ATD associated liver disease, and pulmonary disease, such as, A1ATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting A1AT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, A1ATD associated liver disease and pulmonary disease, such as, A1ATD associated pulmonary disease.Type: GrantFiled: April 13, 2016Date of Patent: October 24, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
-
Patent number: 9725722Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TMPRSS6.Type: GrantFiled: November 7, 2012Date of Patent: August 8, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventor: Shuling Guo
-
Patent number: 9714288Abstract: The present disclosure provides compounds comprising modified oligonucleotides and anti-CD22 antibodies. Certain such modified oligonucleotides conjugated to anti-CD22 antibodies are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: GrantFiled: September 30, 2015Date of Patent: July 25, 2017Assignees: The Regents of the University of California, Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Shuling Guo, Noriko Satake, Nitin Nitin, Joseph M. Tuscano
-
Publication number: 20170073688Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TMPRSS6.Type: ApplicationFiled: November 3, 2016Publication date: March 16, 2017Inventor: Shuling Guo
-
Publication number: 20160369275Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: June 23, 2016Publication date: December 22, 2016Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Publication number: 20160362687Abstract: Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, A1ATD associated liver disease, and pulmonary disease, such as, A1ATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting A1AT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, A1ATD associated liver disease and pulmonary disease, such as, A1ATD associated pulmonary disease.Type: ApplicationFiled: April 13, 2016Publication date: December 15, 2016Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
-
Patent number: 9399774Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: GrantFiled: May 20, 2015Date of Patent: July 26, 2016Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Patent number: 9340784Abstract: Disclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, AIATD associated liver disease, and pulmonary disease, such as, AIATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting AIAT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, AIATD associated liver disease and pulmonary disease, such as, AIATD associated pulmonary disease.Type: GrantFiled: March 19, 2013Date of Patent: May 17, 2016Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
-
Publication number: 20160090598Abstract: The present disclosure provides compounds comprising modified oligonucleotides and anti-CD22 antibodies. Certain such modified oligonucleotides conjugated to anti-CD22 antibodies are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: September 30, 2015Publication date: March 31, 2016Inventors: Michael Oestergaard, Punit P. Seth, Shuling Guo, Noriko Satake, Nitin Nitin, Joseph M. Tuscano
-
Publication number: 20150252367Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.Type: ApplicationFiled: May 20, 2015Publication date: September 10, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
-
Publication number: 20150087691Abstract: Disclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, AIATD associated liver disease, and pulmonary disease, such as, AIATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting AIAT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, AIATD associated liver disease and pulmonary disease, such as, AIATD associated pulmonary disease.Type: ApplicationFiled: March 19, 2013Publication date: March 26, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
-
Publication number: 20140309286Abstract: Disclosed herein are antisense compounds and methods for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or ?-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to TM-PRSS6.Type: ApplicationFiled: November 7, 2012Publication date: October 16, 2014Applicant: ISIS PHARMACEUTICALS, INC.Inventor: Shuling Guo